Comparison between Goldline Pharmaceutical IPO and Jivial Industries IPO.
Goldline Pharmaceutical IPO is a SME Fixed Price IPO proposed to list at BSE SME while Jivial Industries IPO is a SME Fixed Price proposed to list at BSE SME.
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Cumulative Capital Pvt.Ltd. | Corporate Makers Capital Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Nirman Share Brokers Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Goldline Pharmaceutical IPO is up to ₹11.02 Cr whereas the issue size of the Jivial Industries IPO is up to ₹0.00 Cr. The final issue price of Goldline Pharmaceutical IPO is ₹43.00 per share and of Jivial Industries IPO is .
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹41.00 per share | |
| Issue Price (Upper) | ₹43.00 per share | |
| Issue Price (Final) | ₹43.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 3000 shares | |
| Fresh Issue Size | 25,62,000 shares | 13,60,000 shares |
| Fresh Issue Size (Amount) | up to ₹11.02 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 2,72,700 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 25,62,000 shares | 16,32,700 shares |
| Issue Size Total (Amount) | up to ₹11.02 Cr | up to ₹0.00 Cr |
Goldline Pharmaceutical IPO opens on May 12, 2026, while Jivial Industries IPO opens on . The closing date of Goldline Pharmaceutical IPO and Jivial Industries IPO is May 14, 2026, and , respectively.
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| Anchor Bid Date | May 11, 2026 | |
| Issue Open | May 12, 2026 | |
| Issue Close | May 14, 2026 | |
| Basis Of Allotment (Tentative) | May 15, 2026 | |
| Initiation of Refunds (Tentative) | May 18, 2026 | |
| Credit of Share (Tentative) | May 18, 2026 | |
| Listing date (Tentative) | May 19, 2026 | |
| Anchor Lockin End date 1 | Jun 14, 2026 | |
| Anchor Lockin End date 2 | Aug 13, 2026 |
Goldline Pharmaceutical IPO P/E ratio is 10.47, as compared to Jivial Industries IPO P/E ratio of .
| Goldline Pharmaceutical IPO | Jivial Industries IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 79.70 | 94.53 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 57.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 10.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹41.28 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 35.83 | 41.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 38.45 | 47.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.50 | 0.04 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.37 | 41.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Goldline Pharmaceutical IPO Retail Individual Investors (RII) are offered 9,00,000 shares while in Jivial Industries IPO retail investors are offered 9,00,000 shares. Qualified Institutional Buyers (QIB) are offered 5,40,000 shares in Goldline Pharmaceutical IPO and 0 shares in Jivial Industries IPO.
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,32,000 shares | 0 shares |
| Market Maker Reservation | 1,38,000 shares | 0 shares |
| QIB | 5,40,000 shares | 0 shares |
| NII | 3,90,000 shares | 0 shares |
| RII | 9,00,000 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 25,62,000 shares | 0 shares |
Goldline Pharmaceutical IPO subscribed 600.53x in total, whereas Jivial Industries IPO subscribed .
| Goldline Pharmaceutical IPO | Jivial Industries IPO | |
|---|---|---|
| QIB (times) | 180.22x | |
| NII (times) | 1,662.04x | |
| Big NII (times) | 2,010.60x | |
| Small NII (times) | 980.75x | |
| RII (times) | 881.15x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 600.53x |
